Aztreonam plus ceftazidime/avibactam broth disk elution test: failure to detect Escherichia coli with PBP-3 insertions
- 24 January 2026
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 45 (5) , 1285-1295
Abstract
Introduction Metallo-β-lactamase (MBL)-producing Enterobacterales are increasing in frequency and treatment options are limited. Aztreonam/avibactam (AZA) and aztreonam (ATM) plus ceftazidime/avibactam (CZA) showed activities against these organisms. Escherichia coli with PBP3 insertions (YRIN, YRIK) showed decreased activities to AZA and have been linked with treatment failures. Methods We used well-characterized global collections of MBL-producing Enterobacterales (n = 86) to evaluate if MICs generated by AZA MIC Test Strips (MTS) could be used as substitute testing for ATM-CZA Broth Disk Elution (ATM-CZA BDE). We also determined if AZA (breakpoint of 4/4 µg/ml) or ATM-CZA BDE could detect E. coli with PBP-3 insertions. Results The AZA MTS at ≤ 2/4µg/ml and ≥ 8/4µg/ml) showed 100% categorical agreement with ATM-CZA BDE but was less labour-intensive and more cost-effective. A strain with AZA MIC of 4/4 µg/ml tested not susceptible with ATM-CZA BDE, resulting in a very major error rate of 1/9 (11%). ATM-CZA BDE and AZA MICs (1–4 µg/ml) reported 76% (42/55) of E. coli with blaNDMs that contained YRIK/YRIN insertions, as susceptible. Conclusions AZA MIC Test Strips can reliably predict ATM-CZA BDE results, except for strains with MICs of 4/4 µg/ml. ATM-CZA BDE failed to detect most of E. coli with PBP-3 insertions. E. coli with AZA MICs ranging from 1/4 to 4/4 µg/ml could be screened for PBP-3 insertions, and patients infected with such isolates, should be monitored for possible treatment failures with AZA or ATM-CZA.Keywords
Funding Information
- Alberta Precision Laboratories
This publication has 34 references indexed in Scilit:
- Mobile genetic elements of global Escherichia coli ST131 clades with carbapenemasesEuropean Journal of Clinical Microbiology & Infectious Diseases, 2025
- Clinical outcomes of patients hospitalized in internal medicine wards adequately treated for bloodstream infections caused by NDM-producing Klebsiella pneumoniae. Results from a real-life retrospective multi-center study in an endemic areaInfection, 2025
- Epidemiology and outcomes associated with MBL-producing Enterobacterales: A systematic literature reviewInternational Journal of Antimicrobial Agents, 2025
- The Challenge of Treating Infections Caused by Metallo‐β‐Lactamase–Producing Gram-Negative Bacteria: A Narrative ReviewDrugs, 2024
- Development and validation of a pentaplex PCR assay for rapid detection of blaCTX-M, blaOXA–1, blaCMY, blaNDM and the PBP3 insert in EnterobacteralesIndian Journal of Medical Microbiology, 2024
- Resistance to aztreonam-avibactam among clinical isolates of Escherichia coli is primarily mediated by altered penicillin-binding protein 3 and impermeabilityInternational Journal of Antimicrobial Agents, 2024
- Reduced susceptibility to aztreonam-avibactam conferred by acquired AmpC-type β-lactamases in PBP3-modified Escherichia coliEuropean Journal of Clinical Microbiology & Infectious Diseases, 2024
- Activity of aztreonam/avibactam against metallo-β-lactamase-producing Enterobacterales from the UK: Impact of penicillin-binding protein-3 inserts and CMY-42 β-lactamase in Escherichia coliInternational Journal of Antimicrobial Agents, 2023
- Klebsiella pneumoniae ST147: and then there were three carbapenemasesEuropean Journal of Clinical Microbiology & Infectious Diseases, 2022
- Efficacy of Ceftazidime-avibactam Plus Aztreonam in Patients With Bloodstream Infections Caused by Metallo-β-lactamase–Producing EnterobacteralesClinical Infectious Diseases, 2020